Sarah Moreira 
IBEC ICREA Professor Xavier Trepat has been awarded the Lilly Foundation Award in the category of preclinical research. With this accolade, the Fundación Lilly acknowledges Trepat’s work, distinguished by the application of techniques and concepts from physics to the health sciences.
IBEC researcher Pere Roca-Cusachs has been awarded the “ICREA Academia” distinction by the Catalan Institution for Research and Advanced Studies (ICREA). The leader of IBEC’s Cellular and Molecular Mechanobiology group received the award in the Life & Medical Sciences category.
Two studies led by IBEC have successfully mimicked the transdifferentiation process of the neuroblastoma vasculature in in vitro models. These models, one in 2D and the other on a microfluidic chip, provide platforms for identifying new biomarkers and designing effective therapies against this type of cancer.
This accreditation, granted by the Ministry of Science, Innovation and Universities, recognizes the relevance and impact of IBEC’s research results internationally and entails funding of 4.5 million euros over 4 years.
Today, on March 14th, the joint ICMS-IBEC symposium took place. This event was co-organized by IBEC and the Institute for Complex Molecular Systems (ICMS). Throughout the conference, researchers from both IBEC and ICMS presented their areas of research, aiming to enhance the scientific collaboration between the two institutions.
Today, the event “Advances in Ataxia Telangiectasia” took place, organized by the Institute of Bioengineering of Catalonia (IBEC) in collaboration with AEFAT, the Spanish ataxia-telangiectasia family association. The gathering brought together patients’ families, researchers, and clinicians to explore the latest advancements in the clinical management of ataxia telangiectasia.
The project focuses on developing a chip that will serve as a model for testing new drugs to treat neuroblastoma, a childhood brain cancer. The research has received €200,000 in funding and is led by Aránzazu Villasante, Senior Researcher at IBEC.
A study led by IBEC and ISGlobal has demonstrated the antileishmanial potential of an antimalarial compound. Initially designed for malaria, this drug shows high efficacy against leishmaniasis, representing a unique and promising breakthrough for the treatment of both infections.
Experts in nanomedicine from various fields have gathered today for the fifth consecutive year at Nano Rare Diseases Day. This event is co-organized by the NANOMED Spain platform, coordinated by IBEC, and SJD Barcelona Children’s Hospital, showcasing the latest advances in nanomedicine for the diagnosis and treatment of rare diseases.
From February 14 to 16, IBEC hosted 20 research managers from Widening countries. This initiative, promoted by the NCP_WIDERA.NET project, aims for these managers to acquire the best practices of centers of excellence to apply them in their own institutions and explore possible synergies.